EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC0

Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial

Stephen R Walsh iD, Cynthia L Gay, Shelly T Karuna, Ollivier Hyrien, Timothy Skalland iD, Kenneth H Mayer iD, Magdalena E Sobieszczyk, Lindsey R Baden, Paul A Goepfert, Carlos Del Rio, Guiseppe Pantaleo iD, Philip Andrew und 22 weitere

PLOS Medicine · 24.06.2024 · 21 (6) · e1004329

DOI: 10.1371/journal.pmed.1004329 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift PLOS Medicine, online erschienen am 24.06.2024. Verfasst von Stephen R Walsh und 33 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, HIV Antibodies. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75% prevention efficacy against highly neutralization-sensitive viruses but was ineffective against less sensitive viruses. VRC07-523LS is a next-generation bnAb targeting the CD4-binding site and was engineered for increased neutralization breadth and half-life. We conducted a multicenter, randomized, partially blinded Phase I clinical trial to evaluate the safety and serum concentrations of VRC07-523LS, administered in multiple doses and routes to healthy adults without HIV. Methods and findings Participants were recruited between 2 February 2018 and 9 October 2018. A total of 124 participants were randomized to receive 5 VRC07-523LS administrations via IV (T1: 2.5 mg/kg, T2: 5 mg/kg, T3: 20 mg/kg), subcutaneous (SC) (T4: 2.5 mg/kg, T5: 5 mg/kg), or intramuscular (IM) (T6: 2.5 mg/kg or P6: placebo) routes at 4-month intervals. Participants and site staff were blinded to VRC07-523LS versus placebo for the IM group, while all other doses and routes were open-label. Safety data were collected for 144 weeks following the first administration. VRC07-523LS serum concentrations were measured by ELISA through Day 112 in all participants and by binding antibody multiplex assay (BAMA) thereafter in 60 participants (10 per treatment group) through Day 784. Compartmental population pharmacokinetic (PK) analyses were conducted to evaluate the VRC07-523LS serum PK. Neutralization activity was measured in a TZM-bl assay and antidrug antibodies (ADAs) were assayed using a tiered bridging assay testing strategy. Injections and infusions were well tolerated, with mild pain or tenderness reported commonly in the SC and IM groups, and mild to moderate erythema or induration reported commonly in the SC groups. Infusion reactions were reported in 3 of 20 participants in the 20 mg/kg IV group. Peak geometric mean (GM) concentrations (95% confidence intervals [95% CIs]) following the first administration were 29.0 μg/mL (25.2, 33.4), 58.5 μg/mL (49.4, 69.3), and 257.2 μg/mL (127.5, 518.9) in T1-T3 with IV dosing; 10.8 μg/mL (8.8, 13.3) and 22.8 μg/mL (20.1, 25.9) in T4-T5 with SC dosing; and 16.4 μg/mL (14.7, 18.2) in T6 with IM dosing. Trough GM (95% CIs) concentrations immediately prior to the second administration were 3.4 μg/mL (2.5, 4.6), 6.5 μg/mL (5.6, 7.5), and 27.2 μg/mL (23.9, 31.0) with IV dosing; 0.97 μg/mL (0.65, 1.4) and 3.1 μg/mL (2.2, 4.3) with SC dosing, and 2.6 μg/mL (2.05, 3.31) with IM dosing. Peak VRC07-523LS serum concentrations increased linearly with the administered dose. At a given dose, peak and trough concentrations, as well as serum neutralization titers, were highest in the IV groups, reflecting the lower bioavailability following SC and IM administration. A single participant was found to have low titer ADA at a lone time point. VRC07-523LS has an estimated mean half-life of 42 days across all doses and routes (95% CI: 40.5, 43.5), over twice as long as VRC01 (15 days).

Conclusions

VRC07-523LS was safe and well tolerated across a range of doses and routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.

Trial registration

ClinicalTrials.gov/ NCT03387150 (posted on 21 December 2017).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingHIV AntibodiesHumansMaleFemaleAdultMiddle AgedHIV InfectionsHIV-1Young AdultBroadly Neutralizing AntibodiesAdolescentInjections, Intramuscular

Substanzen

Antibodies, NeutralizingHIV AntibodiesBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Harvard Medical School, Boston, Massachusetts, United States of America.
  • Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
  • Fenway Institute, Boston, Massachusetts, United States of America.
  • Division of Infectious Diseases, Columbia University, New York, New York, United States of America.

ORCID-Profile: Stephen R Walsh, Timothy Skalland, Kenneth H Mayer, Guiseppe Pantaleo, Huiyin Lu, Carmen A Paez, Laura L Polakowski, Julie Dumond, Margaret E Ackerman, Estelle Piwowar-Manning, Kelly Seaton, Georgia D Tomaras, David C Montefiori, John R Mascola

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • NCRR NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Walsh, S. R., Gay, C. L., Karuna, S. T., Hyrien, O., Skalland, T., Mayer, K. H., Sobieszczyk, M. E., Baden, L. R., Goepfert, P. A., Del Rio, C., Pantaleo, G., Andrew, P., Karg, C., He, Z., Lu, H., Paez, C. A., Baumblatt, J. A. G., Polakowski, L. L., Chege, W., …, & HVTN 127/HPTN 087 Study Team (2024). Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial. PLOS Medicine, 21(6), e1004329. https://doi.org/10.1371/journal.pmed.1004329

Vancouver

Walsh SR, Gay CL, Karuna ST, Hyrien O, Skalland T, Mayer KH, et al. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial. PLOS Medicine. 2024;21(6):e1004329. doi:10.1371/journal.pmed.1004329

BibTeX
@article{Walsh2024,
  author = {Walsh, Stephen R and Gay, Cynthia L and Karuna, Shelly T and Hyrien, Ollivier and Skalland, Timothy and Mayer, Kenneth H and Sobieszczyk, Magdalena E and Baden, Lindsey R and Goepfert, Paul A and Del Rio, Carlos and Pantaleo, Guiseppe and Andrew, Philip and Karg, Carissa and He, Zonglin and Lu, Huiyin and Paez, Carmen A and Baumblatt, Jane A G and Polakowski, Laura L and Chege, Wairimu and Anderson, Maija A and Janto, Sophie and Han, Xue and Huang, Yunda and Dumond, Julie and Ackerman, Margaret E and McDermott, Adrian B and Flach, Britta and Piwowar-Manning, Estelle and Seaton, Kelly and Tomaras, Georgia D and Montefiori, David C and Gama, Lucio and Mascola, John R and HVTN 127/HPTN 087 Study Team, HVTN 127/HPTN 087 Study Team},
  title = {Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial},
  journal = {PLOS Medicine},
  year = {2024},
  volume = {21},
  number = {6},
  pages = {e1004329},
  doi = {10.1371/journal.pmed.1004329}
}
Kostenlos starten →